drugset / Trial / NCT05523570
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.
Timeline
- Start
- 2022-08-22
- Primary completion
- 2024-04-15
- Completion
- 2024-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HNC364 | Unknown | 20 mg | Intramuscular |
| Subject | HNC364 | Unknown | 40 mg | Intramuscular |
| Subject | HNC364 | Unknown | 60 mg | Intramuscular |
| Subject | HNC364 | Unknown | 80 mg | Intramuscular |